Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma
Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma
Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer PFS than temozolomide alone
ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC
Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC
Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas
Comment: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas
Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas
COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03
Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC
Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients